Clinical Trials (PDQ®)
|Phase III||Biomarker/Laboratory analysis, Treatment||Completed||18 and over||Pharmaceutical / Industry||BO18602|
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva and that of standard of care chemotherapy in patients with advanced, recurrent, or metastatic NSCLC experiencing disease progression after failure of platinum-based chemotherapy.Eligible patients will be randomized to receive either Tarceva 150mg po daily, or comparator (either Alimta 500mg/m2 every 3 weeks, or Taxotere 75mg/m2 every 3 weeks). The anticipated time on study treatment is until disease progression ,and the target sample size is 500+ individuals.
- adult patients >=18 years of age;
- histologically documented, locally advanced or recurrent or metastatic NSCLC;
- measurable disease;
- disease progression during 1-4 cycles of platinum-based chemotherapy.
- any other malignancies within the last 5 years;
- unstable systemic disease.
Trial Lead Organizations/Sponsors
F. Hoffmann - La Roche, Limited
|Clinical Trials||Study Director|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00556322
ClinicalTrials.gov processed this data on January 20, 2015
Back to Top